Outcome of COVID-19 in Patients withMyasthenia May Not Only Depend on the Immunologic Disease
DOI:
https://doi.org/10.47310/iarjmsr.2020.V01i02.04Keywords:
myasthenia, COVID-19, SARS-CoV-2, neuromuscular transmission.Abstract
With interest we read the article by Camelo-Filho et al., (2020) about 15 patients with myasthenia gravis (MG) admitted to four hospitals in Sao Paolo because of an infection with SARS-CoV-2 (COVID-19). The authors found that most MG patients developed a severe course of COVID-19, such that 87% of the MG patients required transfer to the intensive care unit (ICU), that 73% required artificial ventilation, and that 30% of these patients died. We have the following comments and concerns.